Cargando…
P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS
Autores principales: | Hermans, Sjoerd, van Norden, Yvette, van Werkhoven, Erik, Dinmohamed, Avinash, Huijgens, Peter, Ossenkoppele, Gert, Huls, Gerwin, Löwenberg, Bob, Pabst, Thomas, Breems, Dimitri, Postmus, Douwe, Pignatti, Francesco, Versluis, Jurjen, Cornelissen, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428865/ http://dx.doi.org/10.1097/01.HS9.0000969164.32364.1c |
Ejemplares similares
-
The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
por: Bakunina, Katerina, et al.
Publicado: (2021) -
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
por: Brune, Magdalena M., et al.
Publicado: (2021) -
P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
por: Tettero, Jesse, et al.
Publicado: (2023) -
Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014) -
Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial
por: Ngai, Lok Lam, et al.
Publicado: (2023)